Form 4: Teleflex Director Neena M. Patil Reports Stock Option Grant and RSU Award

Director Neena M. Patil reports the acquisition of stock options and restricted stock units (RSUs) in Teleflex Inc.

Summary

• On May 7, 2024, Neena M. Patil, a director of Teleflex Inc. (TFX), reported transactions involving Teleflex's common stock.
• Patil was granted 1,349 stock options with an exercise price of $201.52, exercisable starting May 7, 2025, and expiring on May 7, 2034.
• She also received a Restricted Stock Unit (RSU) award of 649 shares, vesting on the one-year anniversary of the grant date, with a condition related to her re-election to the board at the 2025 annual meeting.
• Following these transactions, Patil directly owns 1,349 derivative securities and 1,575 shares of Teleflex common stock.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. It reflects standard insider activity related to compensation, indicating confidence from the director in the company's future.

Positives

• The grant of stock options and RSUs aligns the director's interests with those of the shareholders.
• The vesting conditions on the RSU award incentivize the director to remain on the board.

Future Outlook

The document does not contain specific forward-looking statements about the company's future performance, but the equity grants suggest an expectation of continued service and contribution from the director.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies to align management and board member interests with shareholder value. Equity grants are a standard component of executive compensation packages in the medical device industry.

Comparison to Industry Standards

• Equity compensation is a common practice among publicly traded companies, particularly in the medical device industry.
• Companies like Medtronic, Stryker, and Boston Scientific also utilize stock options and restricted stock units as part of their executive compensation packages.
• The vesting schedules and exercise prices are generally aligned with industry norms to incentivize long-term performance and retention.

Stakeholder Impact

• The equity grants align the director's interests with those of shareholders, potentially leading to decisions that benefit shareholder value.
• The grants can also serve as an incentive for the director to remain on the board, providing stability and experience.

Key Dates